Century Therapeutics

Century Therapeutics is a biotech company developing novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies.

Century Therapeutics is focused on developing induced pluripotent stem cell- (iPSC) based therapies for the treatment of hematologic and solid malignancies.

Century was founded in 2018 by Versant and quickly formed a strategic partnership with Fujifilm Cellular Dynamics Inc. (FCDI), a subsidiary of Fujifilm Corporation, to develop iPSC-derived immune effector cells for cancer. The company has it's headquartered based in Philadelphia, Pennsylvania.

Century Therapeutics harnesses the power of adult stem cells to develop curative therapies for cancer.

Century's genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. It's commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.

 

Century Therapeutics' dedicated team is developing novel allogeneic living cell products for oncology that overcome the limitations of first-generation cell therapies.

 

Century is backed by Leaps by Bayer, Casdin Capital, Versant, Fidelity Management & Research LLC, RA Capital, OrbiMed, FUJIFILM and others. The company raised $160M in a Series C round on Mar 03, 2021. This brings Century's total funding to $410M to date.

 

 

  • Year founded: 2018
  • Funding Info: $410M over 2 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Philadelphia
  • State: Pennsylvania
  • Country: United States
Related businesses